Recombinant Human UBE2E3 protein

中文名： 泛素结合酶E2E3(UBE2E3)重组蛋白
别名： UBE2E3；UBCE4；Ubiquitin-conjugating enzyme E2 E3

货号: PA1000-3370

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	UBE2E3
Uniprot No	Q969T4
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	2-207aa
氨基酸序列	SSDRQRSDD ESPSTSSGSS DADQRDPAAP EPEEQEERKP SATQQKKNTK LSSKTTAKLS TSAKRIQKEL AEITLDPPPN CSAGPKGDNI YEWRSTILGP PGSVYEGGVF FLDITFSSDY PFKPPKVTFR TRIYHCNINS QGVICLDILK DNWSPALTIS KVLLSICSLL TDCNPADPLV GSIATQYLTN RAEHDRIARQ WTKRYAT
预测分子量	kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于UBE2E3重组蛋白的3篇代表性文献概览：

---

1. **文献名称**: "UBE2E3 ubiquitin-conjugating enzyme regulates proteasome-mediated degradation of p21"

**作者**: Nakagawa et al. (2018)

**摘要**: 研究揭示了UBE2E3通过泛素化修饰细胞周期调控蛋白p21.促进其被蛋白酶体降解的机制，并利用重组UBE2E3蛋白验证了其在体外泛素化反应中的催化活性。

2. **文献名称**: "Structural insights into UBE2E3-ubiquitin interaction and its role in neurodegenerative diseases"

**作者**: Chen et al. (2020)

**摘要**: 通过X射线晶体学解析了重组UBE2E3蛋白与泛素分子的复合物结构，阐明了其催化结构域的关键结合位点，并发现其功能异常与阿尔茨海默病中蛋白质聚集相关。

3. **文献名称**: "Recombinant UBE2E3 expression and enzymatic characterization in cancer cell models"

**作者**: Gupta & Harper (2021)

**摘要**: 报道了重组UBE2E3蛋白在大肠杆菌中的高效表达与纯化方法，并在体外验证了其在多种肿瘤细胞系中对促癌底物的泛素化修饰活性，提示其作为潜在治疗靶点。

---

**备注**：以上文献信息为基于领域知识的概括性示例，实际文献需通过PubMed、Web of Science等平台检索确认。

背景信息

**Background of UBE2E3 Recombinant Protein**

UBE2E3 (Ubiquitin-Conjugating Enzyme E2 E3) is a member of the E2 ubiquitin-conjugating enzyme family, which plays a critical role in the ubiquitin-proteasome system (UPS). This system governs protein degradation, post-translational modification, and regulation of cellular processes such as DNA repair, cell cycle progression, and signal transduction. UBE2E3 specifically facilitates the transfer of ubiquitin from E1 ubiquitin-activating enzymes to substrate proteins, often in collaboration with E3 ubiquitin ligases, marking targets for proteasomal degradation or functional modulation.

Structurally, UBE2E3 contains a conserved catalytic core domain typical of E2 enzymes, essential for its interaction with E1 and E3 enzymes. Its C-terminal region influences substrate specificity and subcellular localization. Dysregulation of UBE2E3 has been linked to diseases, including cancers and neurodegenerative disorders, due to its role in controlling key regulatory proteins like tumor suppressors or oncoproteins.

Recombinant UBE2E3 protein is produced via genetic engineering, often expressed in *E. coli* or mammalian systems, followed by purification to ensure high specificity and activity. This engineered protein retains enzymatic functionality, enabling researchers to study ubiquitination mechanisms *in vitro*, screen for modulators, or investigate disease-related pathways. Its applications extend to elucidating substrate recognition, E3 ligase partnerships, and developing therapeutic strategies targeting the UPS.

Studies using recombinant UBE2E3 have highlighted its involvement in diverse pathways, such as the Wnt/β-catenin signaling and p53 regulation, underscoring its therapeutic potential. Continued research aims to unravel its tissue-specific roles and exploit its enzymatic activity for precision medicine in ubiquitination-dependent pathologies.